Pnina Fishman
Company: CanFite
Job title: Chief Executive Officer
Seminars:
A Phase 2a Dosefinding Study of Namodenoson, an A3AR Agonist, in Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis 1:30 pm
• General background of our target • Revealing our protocol and study results • How we designed our Phase 2a trialRead more
day: Day 2 Stream 3 PM